AQP4 and stroke disorder: However, careful strategies are required, potentially genotype-guided or guided by biomarker levels, to decide when inhibiting or augmenting AQP4 might benefit patients after stroke; robust longitudinal and randomized clinical trials are required to properly determine the benefit of AQP4 targeting in stroke.